Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040-Reference-Cited by-同舟云学术

Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

Published:2023-12 Issue: Volume: Page:
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

El-Khoueiry A.B.,Trojan J.,Meyer T.,Yau T.,Melero I.,Kudo M.,Hsu C.,Kim T.-Y.,Choo S.-P.,Kang Y.-K.,Yeo W.,Chopra A.,Soleymani S.,Yao J.,Neely J.,Tschaika M.,Welling T.H.,Sangro B.

Funder

Ipsen Biopharmaceuticals

Bristol-Myers Squibb Co

Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference41 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

3. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma;Abou-Alfa;NEJM Evid,2022

4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatocellular carcinoma V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.

5. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA;Abou-Alfa;J Clin Oncol,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood MALT1 serves as a potential biomarker reflecting the response and survival of immune‑checkpoint‑inhibitor therapy in advanced hepatocellular carcinoma;Oncology Letters;2024-08-05

2. Recent Advances in Liver Transplantation for Hepatocellular Carcinoma;Current Treatment Options in Oncology;2024-08-01

3. Inflammation of the liver, HCC development and HCC establishment;Hepatology International;2024-06-28

4. Treatment options for advanced hepatocellular carcinoma: the potential of biologics;Expert Opinion on Biological Therapy;2024-06-02

5. Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma;Cancers;2024-05-12